Literature DB >> 29898493

Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.

Maria Eleftheria Evangelopoulos1,2, Andrei Miclea2, Lisa Schrewe2, Myriam Briner2, Anke Salmen2, Britta Engelhardt3, Andrea Huwiler4, Andrew Chan2, Robert Hoepner2.   

Abstract

Entities:  

Keywords:  zzm321990FTYzzm321990; Disease activity; Disease reactivation; Gilenya; MS relapse

Mesh：

Substances：

Year:  2018        PMID： 29898493      PMCID： PMC6489842          DOI： 10.1111/cns.12992

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN： 1755-5930            Impact factor:   5.243


× No keyword cloud information.
  7 in total

1.  Age-dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross-sectional study.

Authors:  Andrei Miclea; Anke Salmen; Greta Zoehner; Lara Diem; Christian P Kamm; Panos Chaloulos-Iakovidis; Marius Miclea; Myriam Briner; Kostas Kilidireas; Leonidas Stefanis; Andrew Chan; Maria Eleftheria Evangelopoulos; Robert Hoepner
Journal:  CNS Neurosci Ther       Date:  2018-11-08       Impact factor: 5.243

2.  Neuronal Metabolism and Neuroprotection: Neuroprotective Effect of Fingolimod on Menadione-Induced Mitochondrial Damage.

Authors:  Antonio Gil; Elisa Martín-Montañez; Nadia Valverde; Estrella Lara; Federica Boraldi; Silvia Claros; Silvana-Yanina Romero-Zerbo; Oscar Fernández; Jose Pavia; Maria Garcia-Fernandez
Journal:  Cells       Date:  2020-12-29       Impact factor: 6.600

Review 3.  Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.

Authors:  Kerri A Schoedel; Carine Kolly; Anne Gardin; Srikanth Neelakantham; Kasra Shakeri-Nejad
Journal:  Psychopharmacology (Berl)       Date:  2021-11-13       Impact factor: 4.530

4.  Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.

Authors:  Assunta Bianco; Matteo Lucchini; Rocco Totaro; Roberta Fantozzi; Giovanna De Luca; Sonia Di Lemme; Giorgia Presicce; Luana Evangelista; Valeria Di Tommaso; Roberta Pastorino; Chiara De Fino; Valeria De Arcangelis; Diego Centonze; Massimiliano Mirabella
Journal:  Neurotherapeutics       Date:  2021-09-07       Impact factor: 7.620

5.  Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.

Authors:  D Mickeviciene; A Baltusiene; B Afanasjeva; D Afanasjevas; R Gleizniene; D Rastenyte; J R Berger
Journal:  BMC Neurol       Date:  2022-08-19       Impact factor: 2.903

Review 6.  Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.

Authors:  Isabella Laura Simone; Carla Tortorella; Alma Ghirelli
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

7.  Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: A case study.

Authors:  Beatriz Canibaño; Musab Ali; Boulenouar Mesraoua; Gayane Melikyan; Hasan Al Hail; Faiza Ibrahim; Yolande Hanssens; Dirk Deleu
Journal:  Case Rep Womens Health       Date:  2019-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.